文献速递胸部心血管CT

非癌性胸部CT特征对接受立体定向体部放疗的I期肺癌患者总生存期和非癌性死亡的预测价值

Utility of Noncancerous Chest CT Features for Predicting Overall Survival and Noncancer Death in Patients With Stage I Lung Cancer Treated With Stereotactic Body Radiotherapy.
PubMed 文献 · AJR Am J Roentgenol · 2022-04-13

回顾性纳入2009年1月至2017年6月接受SBRT的282例I期肺癌患者,用治疗前胸部CT量化冠脉钙化积分、肺动脉/主动脉比、肺气肿及T5/T8/T10层面体成分。中位随访60.8个月,148例死亡(其中83例非癌性死亡)。较高冠脉钙化积分、较高肺动脉/主动脉比和较低胸廓骨骼肌指数独立预测较差总生存期;联合临床与影像特征的模型5年OS的AUC为0.75,优于仅临床特征模型的0.61(P<.01)。

要点

  • 冠脉钙化积分11–399(HR 1.83)和≥400(HR 1.63)均与较短OS独立相关。
  • 肺动脉/主动脉比每增加0.1单位,OS的HR为1.33(95%CI 1.16–1.52)。
  • 胸廓骨骼肌指数每增加10 cm²/m²,OS的HR为0.88(95%CI 0.79–0.98)。

核心结论

  • 在接受SBRT的I期肺癌患者中,较高冠脉钙化积分、较高肺动脉/主动脉比和较低胸廓骨骼肌指数独立预测较差总生存期;治疗前胸部CT的非癌性影像特征较单独临床特征改善生存预测。

研究设计与样本

  • 回顾性研究纳入282例(168例女性、114例男性,中位年龄75岁)2009年1月至2017年6月接受SBRT的I期肺癌患者,用治疗前胸部CT量化冠脉钙化积分、肺动脉/主动脉比、肺气肿及T5、T8、T10椎体层面骨骼肌和皮下脂肪的横截面积与衰减。

诊断标准与关键数值

  • 较高冠脉钙化积分(11–399:HR 1.83,95%CI 1.15–2.91,P=.01;≥400:HR 1.63,95%CI 1.01–2.63,P=.04)、较高肺动脉/主动脉比(每增加0.1单位:HR 1.33,95%CI 1.16–1.52,P<.001)和较低胸廓骨骼肌指数(每增加10 cm²/m²:HR 0.88,95%CI 0.79–0.98,P=.02)与较短OS独立相关。

临床应用与阅片要点

  • 联合临床与影像特征的模型对5年OS的判别能力优于仅临床特征模型(AUC 0.75 [95%CI 0.68–0.83] vs 0.61 [95%CI 0.53–0.70],P<.01);按平均标准化回归系数,模型中最重要的临床或影像特征为肺动脉/主动脉比。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Noncancerous imaging markers can be readily derived from pre-treatment diagnostic and radiotherapy planning chest CT examinations. OBJECTIVE. The purpose of this article was to explore the ability of noncancerous features on chest CT to predict overall survival (OS) and noncancer-related death in patients with stage I lung cancer treated with stereotactic body radiation therapy (SBRT). METHODS. This retrospective study included 282 patients (168 female, 114 male; median age, 75 years) with stage I lung cancer treated with SBRT between January 2009 and June 2017. Pretreatment chest CT was used to quantify coronary artery calcium (CAC) score, pulmonary artery (PA)-to-aorta ratio, emphysema, and body composition in terms of the cross-sectional area and attenuation of skeletal muscle and subcutaneous adipose tissue at the T5, T8, and T10 vertebral levels. Associations of clinical and imaging features with OS were quantified using a multivariable Cox proportional hazards (PH) model. Penalized multivariable Cox PH models to predict OS were constructed using clinical features only and using both clinical and imaging features. The models' discriminatory ability was assessed by constructing time-varying ROC curves and computing AUC at prespecified times. RESULTS. After a median OS of 60.8 months (95% CI, 55.8-68.0), 148 (52.5%) patients had died, including 83 (56.1%) with noncancer deaths. Higher CAC score (11-399: hazard ratio [HR], 1.83 [95% CI, 1.15-2.91], p = .01; ≥ 400: HR, 1.63 [95% CI, 1.01-2.63], p = .04), higher PA-to-aorta ratio (HR, 1.33 [95% CI, 1.16-1.52], p < .001, per 0.1-unit increase), and lower thoracic skeletal muscle index (HR, 0.88 [95% CI, 0.79-0.98], p = .02, per 10-cm2/m2 increase) were independently associated with shorter OS. Discriminatory ability for 5-year OS was greater for the model including clinical and imaging features than for the model including clinical features only (AUC, 0.75 [95% CI, 0.68-0.83] vs 0.61 [95% CI, 0.53-0.70]; p < .01). The model's most important clinical or imaging feature according to mean standardized regression coefficients was the PA-to-aorta ratio. CONCLUSION. In patients undergoing SBRT for stage I lung cancer, higher CAC score, higher PA-to-aorta ratio, and lower thoracic skeletal muscle index independently predicted worse OS. CLINICAL IMPACT. Noncancerous imaging features on chest CT performed before SBRT improve survival prediction compared with clinical features alone.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Tahir, Marquardt, Mercaldo, et al. Utility of Noncancerous Chest CT Features for Predicting Overall Survival and Noncancer Death in Patients With Stage I Lung Cancer Treated With Stereotactic Body Radiotherapy. AJR Am J Roentgenol. 2022. PMID: 35416054. doi:10.2214/AJR.22.27484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。